Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
INSV: Merged with Thea Acquisition Corp.; $0.35 per share.
FINRA deleted symbol:
http://otce.finra.org/DLDeletions
Is Sun Pharma private? If so, are we looking at a reverse merger? Could be big if Sun has the means to present an 'all cash offer'
http://finance.yahoo.com/news/insite-vision-sun-pharma-enter-202400378.html
"ALAMEDA, Calif.--(BUSINESS WIRE)--
InSite Vision Inc. (INSV) today announced that InSite and a subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma) have entered into a merger agreement under which an indirect wholly owned subsidiary of Sun Pharma will acquire InSite in an all-cash transaction for $0.35 per share, or approximately $48 million in aggregate equity value, on a fully diluted basis. The transaction has been approved by the boards of directors of both InSite and the Sun Pharma subsidiary, and will be completed by means of a tender offer.
InSite also announced that it has terminated its previously announced second amended and restated merger agreement with QLT Inc. Following discussion with both Sun Pharma and QLT, and in consultation with its outside legal and financial advisors, the InSite Board of Directors determined that the Sun Pharma transaction represented a Company Superior Proposal under the QLT merger agreement. In connection with InSite’s termination of the QLT merger agreement, InSite was required to pay a $2,667,000 termination fee to QLT. The Sun Pharma subsidiary has paid this fee to QLT on InSite’s behalf." [more]
hopefully, the news is that a company ssaid they would pay 1.00 per share. that would be nice lol.
I find it interesting that the company chose not to release any news yesterday or today. Negotiations were set to conclude EOB yesterday PST. Hmmmm....
$INSV congrats I believe this the second attempted acquisition of an ophthalmic co. trading on the OTC in the last week. The first one was for UVIC or Unilens Vision FWIW.
$INSV recent news/filings
bullish
threre is a bidding contest between parties to buyout fhe company
Mystery, intrigue as biotech M&A explodes
http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/09/biotech-mergers-acquisitions-insv-qlti-depo-hznp.html
## source: finance.yahoo.com
Sat, 05 Sep 2015 01:16:13 GMT ~ QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
[at noodls] - VANCOUVER, British Columbia, Sept. 4, 2015 (GLOBE NEWSWIRE) -- QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ('QLT' or the 'Company') announces that it has been advised by InSite Vision Incorporated ('InSite') that ...
read full: http://www.noodls.com/view/F9D33D0615D6E0C3E72D399997439296C6CA8638
*********************************************************
Fri, 04 Sep 2015 22:16:14 GMT ~ InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
[at noodls] - InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a 'Company Superior Proposal' Bidder Favorably Concludes ...
read full: http://www.noodls.com/view/3F5E9325E5FFC509C01F163E93C68A302010A702
*********************************************************
Fri, 04 Sep 2015 22:15:03 GMT ~ Mystery, intrigue as biotech M&A explodes
read full: http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/09/biotech-mergers-acquisitions-insv-qlti-depo-hznp.html?ana=yahoo
*********************************************************
Fri, 04 Sep 2015 21:49:00 GMT ~ InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
[Business Wire] - InSite Vision Inc. today announced that InSite’s Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a “Company Superior Proposal” as defined in InSite’s previously announced definitive agreement with QLT Inc.
read full: http://finance.yahoo.com/news/insite-vision-determines-unsolicited-offer-214900847.html
*********************************************************
Fri, 04 Sep 2015 21:20:32 GMT ~ INSITE VISION INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/150904/insv8-k.html
*********************************************************
$INSV charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$INSV company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/INSV/company-info
Ticker: $INSV
OTC Market Place: OTCQB
CIK code: 0000802724
Company name: InSite Vision, Inc.
Company website: http://www.insitevision.com
Incorporated In: DE, USA
Business Description: InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician.AzaSite was launched in the United States in August 2007 by Inspire Pharmaceuticals, InSite Vision's commercial partner for the U.S. and Canada. The company's product development portfolio also includes ISV-502 (AzaSite Plus), which is currently in Phase 3 pivotal trials for the treatment of eyelid infection and inflammation, and additional product candidates leveraging the company's core DuraSite technology platform. InSite has recently advanced two new product candidates for the treatment of eye pain and inflammation into preclinical testing.InSite Vision's strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for its DuraSite-enabled early-stage product candidates, and applying the company's expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.Less >>
$INSV share structure
## source: otcmarkets.com
Market Value: $44,203,596 a/o Sep 04, 2015
Shares Outstanding: 131,951,033 a/o Feb 24, 2015
Float: Not Available
Authorized Shares: 240,000,000 a/o Feb 12, 2015
Par Value: 0.01
$INSV extra dd links
Company name: InSite Vision, Inc.
Company website: http://www.insitevision.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/INSV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/INSV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=INSV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=INSV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=INSV+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/INSV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/INSV/news - http://finance.yahoo.com/q/h?s=INSV+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/INSV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/INSV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/INSV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/INSV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/INSV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/INSV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/INSV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/INSV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=INSV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/INSV
DTCC (dtcc.com): http://search2.dtcc.com/?q=InSite+Vision%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=InSite+Vision%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=InSite+Vision%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.insitevision.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.insitevision.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.insitevision.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/INSV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/INSV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/INSV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/INSV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/INSV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000802724&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/INSV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/INSV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/INSV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/INSV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=INSV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=INSV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/INSV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=INSV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=INSV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=INSV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=INSV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=INSV+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/INSV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=INSV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/INSV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=INSV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/INSV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/INSV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/INSV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/INSV/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/INSV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/INSV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/INSV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=INSV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INSV
$INSV DD Notes ~ http://www.ddnotesmaker.com/INSV
Let the bidding wars begin!
"InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company
(Ref: Business Wire)
September 3rd, 2015
ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite™ patent lawsuit. InSite Vision believes the lawsuit is without merit.
InSite Vision is party to a merger agreement with QLT Inc. pursuant to which QLT would acquire InSite Vision in a transaction in which InSite Vision's stockholders would receive 0.078 QLT shares for each share of InSite Vision stock, subject to a collar arrangement that would limit the maximum value of each share to $0.30, with a minimum value of each share of $0.25.
Consistent with its fiduciary duties and in accordance with its existing merger agreement with QLT, InSite Vision's Board of Directors, in consultation with its financial and legal advisors, will carefully review all aspects of the new proposal and pursue the course of action that it believes is in the best interests of InSite Vision's stockholders. InSite Vision stockholders do not need to take any action at this time.
InSite Vision remains subject to its existing merger agreement with QLT, and the InSite Vision Board of Directors has not changed its recommendation in support of the QLT transaction, the existing merger agreement with QLT or its recommendation that InSite Vision stockholders adopt the existing merger agreement with QLT.
Guggenheim Securities, LLC is acting as financial advisor to InSite Vision, Roth Capital Partners provided an independent fairness opinion and Jones Day is acting as legal advisor to InSite Vision.
About InSite Vision
InSite Vision is advancing new specialty ophthalmic products for the treatment of diseases affecting the front and back of the eye. The company has two commercial products based on its innovative DuraSite® platform approved for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn, Inc., and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite has a proprietary portfolio of clinical-stage product candidates, and has filed a New Drug Applications for commercial approval by the U.S. Food and Drug Administration of BromSite™ for the treatment of inflammation and prevention of pain associated with cataract surgery, and is preparing a New Drug Application for DexaSite™ for the treatment of blepharitis, and for treatment of inflammation associated with cataract surgery. InSite's AzaSite Plus™ is advancing through Phase 3 clinical studies for the treatment of blepharitis, and ISV-101 is ready for Phase 1/2 clinical development for the treatment of severe dry-eye disease due to inflammation. For further information on InSite Vision, please visit www.insitevision.com.
No Offer or Solicitation
This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Additional Information
In connection with the proposed merger of InSite Vision and QLT, QLT filed with the U.S. Securities and Exchange Commission (SEC) a Registration Statement on Form S-4 that includes a preliminary proxy statement of InSite Vision and that also constitutes a preliminary prospectus of QLT (the Form S-4). The Form S-4 has not yet been declared effective by the SEC and is not complete and will be further amended. InSite Vision plans to mail the definitive proxy statement/prospectus to its stockholders when it becomes available. INVESTORS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement/prospectus (when available) and other documents filed with the SEC by QLT or InSite Vision through the website maintained by the SEC at www.sec.gov and, in QLT's case, also on the System for Electronic Document Analysis Retrieval (SEDAR) website maintained by the Canadian Securities Administrators at www.sedar.com. Copies of the documents filed with the SEC by InSite Vision will be available free of charge on InSite Vision's website at www.InSiteVision.com or by contacting InSite Vision at 510-747-1220.
Participants in the Merger Solicitation
QLT, InSite Vision, their respective directors and certain of their executive officers and employees may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the QLT and InSite Vision shareholders in connection with the proposed merger and a description of their direct and indirect interests, by security holdings or otherwise, will be set forth in the proxy statement/prospectus when it is filed with the SEC. Information about the directors and executive officers of QLT is set forth in its Annual Report on Form 10-K/A, which was filed with the SEC on April 30, 2015. Information about the directors and executive officers of InSite Vision is set forth in its proxy statement for its 2015 annual meeting of shareholders, which was filed with the SEC on February 19, 2015. These documents can be obtained free of charge from the sources indicated above."
http://www.businesswire.com/news/home/20150903006483/en/
INSV left the price out. Can be found is QLTI PR:
Under the terms of the of the definitive agreement and plan of merger, at closing of the InSite Acquisition InSite Vision shareholders will receive 0.048 common shares of QLT for each common share of InSite Vision they own, which equates to a value of $0.178 per InSite Vision share based on QLT's closing share price of $3.71 on June 5, 2015. This represents a 17.3% premium over InSite Vision’s 90-day volume-weighted average share price of $0.152 as of June 5, 2015.
http://ih.advfn.com/p.php?pid=nmona&article=67192847
Why isn't this moving
Merger news out
INSV merger news
InSite Vision To Merge With Canadian Biotechnology Company QLT [Market News Publishing (US)]
INSITE VISION INC
INSITE VISION INC ("INSV-0") QLT INC ("QLT-T;QLTI-Q") - InSite Vision To Merge With Canadian Biotechnology Company QLT
InSite Vision Inc. announced that it has reached a definitive agreement with QLT Inc. under which QLT will acquire InSite in an all-stock transaction that will create an ophthalmic specialty pharmaceutical company with a diversified portfolio of products, full R&D capabilities and innovative platform technologies. The transaction is expected to drive shareholder value by accelerating both companies' development pipelines, increasing product diversity and improving balance sheet strength.
The newly formed company will be incorporated in Canada and led by a combined InSite Vision and QLT leadership team. With operations in Alameda, California and Vancouver, British Columbia, and headquarters in Vancouver, the new company will retain the name of QLT, and will continue to trade on NASDAQ under the ticker "QLTI" and on the Toronto Stock Exchange (TSX) under the ticker "QLT".
InSite Vision plans to promptly file a New Drug Application (NDA) later this week with the U.S. Food and Drug Administration (FDA) for marketing approval of its drug candidate BromSite(TM) to reduce post-operative inflammation and prevent pain following cataract surgery, and continued progression of a Phase 3 clinical trial of QLT091001, QLT's Orphan Drug and FDA Fast Track designated retinoid product candidate for the treatment of inherited retinal diseases in the first half of 2016. The merged companies expect to file a second NDA for InSite Vision's DexaSite(TM) for the treatment of blepharitis in 2016.
The combined company expects to have approximately $70 million in cash after the closing of the transaction and completion of other investments and dividends announced today by QLT, all of which dividends will be effected after the completion of the merger and include distributions to prior InSite shareholders as new QLT shareholders.
"The new company created by this merger will be a well-funded pure play ophthalmic specialty company with a robust pipeline of late-stage drug candidates, a strong cash balance with access to a broader investor base and the opportunity for increased shareholder value," said Timothy Ruane, Chief Executive Officer of InSite Vision. "The combination of InSite Vision with QLT will create a unique new company with multiple potential value creation events in the near- and medium-term, the potential to file multiple NDAs over the next several years, execute on the development of a potential successful ophthalmic retinoid product and advance a diversified pipeline of promising product candidates for unmet eye care needs."
"The merger with InSite Vision is an excellent opportunity for QLT shareholders to benefit from the combined strengths and assets of both companies," said Jason Aryeh, Chairman of QLT. "The InSite Vision team has repeatedly demonstrated its ability to efficiently execute on ophthalmic drug development, and I am excited to see our retinoid product have the opportunity to progress in a similar manner under our combined leadership. With a strong balance sheet and diversified late-stage pipeline, I am excited about the future of the company and its potential for additional value creation."
Zacks upgrades to 1 on Dec 3rd!
InSite Vision, Inc. [$INSV] due diligence
bullish
excellent long term bullish macd bullish divergence
$INSV
DD Notes ~ http://www.ddnotesmaker.com/INSV
##### recent news/filings ~ source: finance.yahoo.com
Tue, 08 Jul 2014 12:49:13 GMT ~ InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults
[at noodls] - DexaSite NDA Submission Planned for 2015; AzaSite Plus™ Data and Endpoint Discussions with FDA Continue European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled for Q3 ...
read full: http://www.noodls.com/view/448A1A5464E62D71A8153AF5D433A244FE358F89
*********************************************************
Tue, 08 Jul 2014 12:30:00 GMT ~ InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults
[Business Wire] - Following a June 16, 2014 meeting with the U.S. Food and Drug Administration , InSite Vision Incorporated today announced that it intends to submit a New Drug Application for DexaSite™ as a treatment for blepharitis in adults during 2015, following completion of remaining chemistry and manufacturing work.
read full: http://finance.yahoo.com/news/insite-vision-plans-submit-drug-123000605.html
*********************************************************
Fri, 13 Jun 2014 20:30:20 GMT ~ INSITE VISION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitiv
read full: http://biz.yahoo.com/e/140613/insv8-k.html
*********************************************************
Thu, 12 Jun 2014 12:32:28 GMT ~ InSite Vision reports agreement with noteholders to extinguish debt
read full: http://www.theflyonthewall.com/permalinks/entry.php/INSVid2024158/INSV-InSite-Vision-reports-agreement-with-noteholders-to-extinguish-debt
*********************************************************
Thu, 12 Jun 2014 12:30:00 GMT ~ InSite Vision Announces Agreement With Noteholders to Extinguish Debt in Exchange for One-Time Payment
[Business Wire] - InSite Vision Incorporated today announced that the Azithromycin PhaRMA Secured 16% Notes due 2019, issued by its wholly owned subsidiary, have been cancelled for a s
read full: http://finance.yahoo.com/news/insite-vision-announces-agreement-noteholders-123000341.html
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/INSV/company-info
Ticker: $INSV
OTC Market Place: OTCQB
CIK code: 0000802724
Company name: InSite Vision, Inc.
Company website: http://www.insitevision.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000802724&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/INSV/filings
Latest financials: http://www.otcmarkets.com/stock/INSV/financials
Latest news: http://www.otcmarkets.com/stock/INSV/news - http://finance.yahoo.com/q/h?s=INSV+Headlines
Major holdings: http://data.cnbc.com/quotes/INSV/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=INSV+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/INSV.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=INSV
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=INSV&search=search
DTCC: http://search2.dtcc.com/?q=InSite+Vision%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=InSite+Vision%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=InSite+Vision%2C+Inc.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.insitevision.com
Alexa: http://www.alexa.com/siteinfo/http://www.insitevision.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.insitevision.com
Short Sales: http://www.otcmarkets.com/stock/INSV/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/INSV/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/INSV/research
Historical Prices: http://finance.yahoo.com/q/hp?s=INSV+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=INSV+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=INSV+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=INSV+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=INSV+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=INSV+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=INSV
Balance Sheet: http://finance.yahoo.com/q/bs?s=INSV
Cash Flow: http://finance.yahoo.com/q/cf?s=INSV+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/INSV
Bloomberg: http://www.bloomberg.com/quote/INSV:US
Morningstar: http://quotes.morningstar.com/stock/s?t=INSV
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INSV
Barchart: http://www.barchart.com/quotes/stocks/INSV
OTC Short Report: http://otcshortreport.com/index.php?index=INSV
Investopedia: http://www.investopedia.com/markets/stocks/INSV/?wa=0
http://www.pennystocktweets.com/stocks/profile/INSV
##### last known share structure ~ source: otcmarkets.com
Market Value: $40,508,967 a/o Jul 11, 2014
Shares Outstanding: 131,951,033 a/o Aug 12, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
##### business description ~ source: otcmarkets.com
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician.AzaSite was launched in the United States in August 2007 by Inspire Pharmaceuticals, InSite Vision's commercial partner for the U.S. and Canada. The company's product development portfolio also includes ISV-502 (AzaSite Plus), which is currently in Phase 3 pivotal trials for the treatment of eyelid infection and inflammation, and additional product candidates leveraging the company's core DuraSite technology platform. InSite has recently advanced two new product candidates for the treatment of eye pain and inflammation into preclinical testing.InSite Vision's strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for its DuraSite-enabled early-stage product candidates, and applying the company's expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.Less >>
DD Notes ~ http://www.ddnotesmaker.com/INSV
a11k
Anything new happening around here? I seen they are canceling some debt or all of it. We should get back into the .30's
Uncle MO is coming to visit after a long downturn here. 0.17 was the jump in number, but it's still not too late.
Zacks strong buy rating. Not too shabby.
I've watched your signature like 10X now! hahahaha
I agree this looks nice, the company is moving along with their studies and has become profitable, hard to find in OTC.
check out whats coming could be a sleeper end of month
Nice chart
No hard DD here yet
What's the common opinion here on price target next 5 weeks?
thx
InSite Vision Completes Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation & Pain Following Ca...
Date : 11/07/2013 @ 4:30PM
Source : Business Wire
Stock : Insite Vision, Inc. (QB) (INSV)
Quote : 0.26 0.02 (8.33%) @ 2:03PM
InSite Vision Completes Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation & Pain Following Ca...
Print
Alert
Insite Vision, Inc. (QB) (USOTC:INSV)
Historical Stock Chart
1 Month : From Oct 2013 to Nov 2013
Click Here for more Insite Vision, Inc. (QB) Charts.
Last Patient Concludes Dosing and Evaluation
InSite Vision Incorporated (OTCBB:INSV) today announced that the last patient has completed dosing and evaluation in the confirmatory Phase 3 clinical trial of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite® drug delivery technology.
InSite Vision expects that top-line data from the BromSite confirmatory Phase 3 clinical trial will be available before the end of 2013. This study enrolled 248 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite against the DuraSite vehicle alone. Patients were randomized and then dosed twice-a-day beginning the day before surgery, continuing the day of surgery and for 14 days post-surgery. The primary study endpoint is the reduction of inflammation after surgery as compared to vehicle, with the secondary endpoint of reduction in pain. The endpoints for the confirmatory study are the same as those used in the prior BromSite Phase 3 clinical trial.
In March 2013, InSite Vision announced positive results from the first Phase 3 clinical study of BromSite. In that study, BromSite achieved statistically significant superiority to vehicle (p<0.001) for primary endpoint of reduction in inflammation. The confirmatory study for BromSite was designed with full input from both the U.S. Food and Drug Administration and the European regulatory authorities. Pharm-Olam International served as the contract research organization managing the BromSite Phase 3 clinical program on behalf of InSite Vision.
About Cataract Surgery
the top line results expected next month will run this to 1
InSite Vision Reports Third Quarter 2013 Financial Results
Date : 11/12/2013 @ 4:03PM
Source : Business Wire
Stock : Insite Vision, Inc. (QB) (INSV)
Quote : 0.26 0.02 (8.33%) @ 2:03PM
InSite Vision Reports Third Quarter 2013 Financial Results
Print
Alert
Insite Vision, Inc. (QB) (USOTC:INSV)
Historical Stock Chart
1 Month : From Oct 2013 to Nov 2013
Click Here for more Insite Vision, Inc. (QB) Charts.
InSite Vision Incorporated (OTCBB:INSV) today reported financial results for the quarter ended September 30, 2013. Revenues for the third quarter of 2013 were $5.3 million compared to $12.1 million for the same period in 2012. Included in the third quarter of 2013 and 2012 were an additional $3.7 million and $9.3 million, respectively, in minimum royalty true-up payments from Merck on net sales of AzaSite. Net income for the third quarter of 2013 was $0.6 million, or less than $0.01 per share, compared to net income of $5.1 million, or $0.04 per share, in the third quarter of 2012.
“InSite is making good progress against our key objectives,” said Timothy Ruane, InSite’s Chief Executive Officer. “We completed our confirmatory Phase 3 study of BromSite for ocular inflammation and pain ahead of schedule and we look forward to reporting that data by year end. We also bolstered our IP portfolio with the receipt of a key patent for our DuraSite 2 platform, which will serve as the foundation for our future ophthalmic therapeutic candidates and is available for licensing to other ophthalmic companies to enhance their products.”
Recent Corporate and Commercial Highlights
In November 2013, InSite completed the confirmatory Phase 3 clinical trial of BromSite™ for the reduction of inflammation and pain after cataract surgery. This study enrolled 248 patients undergoing cataract surgery in a two-arm trial evaluating the efficacy and safety of BromSite against the DuraSite vehicle alone. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite’s DuraSite drug delivery technology. Top-line results from this Phase 3 clinical study are expected before the end of 2013.
Results from InSite’s first Phase 3 pivotal trial demonstrated that treatment with BromSite achieved statistically significant superiority in reducing inflammation and pain compared to treatment with the DuraSite vehicle alone in patients following cataract surgery.
In October 2013, InSite announced that the United States District Court for the District of New Jersey upheld all four of the patents protecting AzaSite® (azithromycin 1% ophthalmic solution) in a patent infringement lawsuit against Sandoz Inc. On November 4, 2013, Sandoz filed an appeal of this decision to the United States Court of Appeals for the Federal Circuit. Sandoz filed an Abbreviated New Drug Application (ANDA) with the FDA in 2011 seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use.
InSite, Merck and Pfizer filed a similar lawsuit against Mylan Pharmaceuticals in June 2013. Mylan recently filed to market a generic version of AzaSite. Merck, with the assistance of InSite and Pfizer, intends to vigorously defend the five U.S. patents related to AzaSite.
On August 1, 2013, Merck notified the Company that it had ceased sales representative promotion of their ophthalmic products, including AzaSite, in the United States. The ophthalmic products, including AzaSite, will continue to be commercially available in the United States and physicians will be able to continue to prescribe the products for their patients. Merck’s obligation to make minimum royalty payments terminated on September 30, 2013.
In August 2013, the United States Patent and Trademark Office (USPTO) issued a patent on DuraSite® 2, the next-generation enhanced drug delivery system. DuraSite 2 provides a broad new platform for developing topically delivered ocular drugs with enhanced tissue penetration in order to improve efficacy and dosing convenience. The patent provides protection to 2029 for the delivery system and drugs that are formulated with DuraSite 2. InSite plans to use the DuraSite 2 platform in the development of all future pipeline products, and initiate a broad licensing program allowing partners exclusive and non-exclusive licensing and/or commercialization relationships.
In July 2013, InSite announced top-line results from the DOUBle Phase 3 clinical study, a multi-product trial evaluating AzaSite Plus™ and DexaSite™ in the treatment of moderate-to-severe blepharitis. While the trial did not meet the primary endpoint of complete resolution of all clinical signs and symptoms, AzaSite Plus and DexaSite demonstrated statistically significant improvements in clinical signs and symptoms of disease at Day 15.
We are in discussions with the U.S. Food and Drug Administration (FDA) to discuss the data from the clinical trial and determine the next steps in the development of these product candidates in the blepharitis indication.
Third Quarter 2013 Results Summary
Total revenues decreased to $5.3 million for the third quarter of 2013 compared to $12.1 million for the same period in 2012. Earned royalties from Merck for net sales of AzaSite were $1.1 million and $2.2 million for the third quarter of 2013 and 2012, respectively. Royalties from Merck included a $3.7 million minimum royalty true-up in the third quarter of 2013 and a $9.3 million minimum royalty true-up for the same period in 2012. The decrease in minimum royalties was primarily driven by an amendment to the payment terms of the Merck License in August 2012 such that Merck will pay on a quarterly basis, the higher of the pro-rata annual minimum royalty or the earned royalty for 2012 and 2013. As such, Merck paid an annual minimum royalty true-up payment in the third quarter of 2012, compared to a quarterly pro-rata share of the minimum royalty amount in the same period of 2013. The required minimum royalty for the fiscal year ended September 30, 2013 and 2012, the measurement period pursuant to the terms of the Merck License, was $19 million and $17 million, respectively. Merck’s obligation to make minimum royalty payments terminated on September 30, 2013. Revenues in the third quarter of 2013 also included $0.5 million from manufacturing equipment rental and the sale of azithromycin to Merck.
Research and development (R&D) expenses for the third quarter of 2013 were $2.5 million compared to $2.6 million in the same period in 2012. For the third quarter of 2013, program expenses were primarily related to costs of InSite’s second BromSite Phase 3 clinical trial. For the third quarter of 2012, program expenses were primarily related to costs of the first BromSite Phase 3 clinical trial and the AzaSite Plus/DexaSite DOUBle Phase 3 clinical study.
General and administrative (G&A) expenses for the third quarter of 2013 were $1.3 million compared to $1.6 million in the same period in 2012. The higher expenses in 2012 were attributable to legal expenses pertaining to patent litigation with the Regents of the University of California.
Net income for the third quarter of 2013 was $0.6 million, or less than $0.01 per share, compared to net income of $5.1 million, or $0.04 per share, in the third quarter 2012. Net income was higher in 2012 primarily due to additional minimum royalties received from Merck.
As of September 30, 2013, InSite had cash, cash equivalents and short-term investments of $11.4 million. Total cash usage in the third quarter of 2013 was $3.2 million.
can this see 1 in the future?
phase 3 results by years end
ALAMEDA, Calif.--(BUSINESS WIRE)--October 07, 2013-- InSite Vision Incorporated (OTCBB: INSV) today announced that the United States District Court for the District of New Jersey upheld all four of the patents protecting AzaSite(R) (azithromycin 1% ophthalmic solution) in a patent infringement lawsuit against Sandoz Inc.
Sandoz filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) in 2011 seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck (NYSE: MRK) in the U.S.
In June 2013 a similar patent infringement lawsuit was filed against Mylan Pharmaceuticals. A trial date in this matter has not been set.
Mylan filed an ANDA application for AzaSite with the FDA of which InSite received notice on May 2, 2013, and InSite had 45 days to file a patent infringement lawsuit. This lawsuit triggered an automatic stay, or bar, of the FDA's approval of the ANDA for up to 30 months or until a final court decision of the infringement lawsuit, whichever comes first.
InSite owns its U.S. patents covering AzaSite and its use, and an exclusive license to a Pfizer-owned azithromycin patent.
~ $INSV ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$INSV has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "INSV" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "INSV": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=INSV ~
Search Ihub for "INSV" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=INSV ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
Not only is B&L going to buy out the royalty stream for the quinalone, they are an excellent candidate to license BromSite in additon to purchasing the company at some point.
At this time, I would put a buy rec on the stock. When the fund, Coliseum Capital Management, LLC, has completed their selling program, the stock will be free to gain value.
A fund who held more than 14.7 million shares last year has been consistently selling for many months and has greatly impacted the price of the stock. This year, they held less than 5% so no form 13G was filed. It will certainly help the share price when their selling program is completed.
Recent conference call indicates Insite is going to sell the royalty stream from their Quinalone licensed and marketed by B&L in order to raise additional cash rather than more dilution. I see that as a positive move.
I think the bad days are over and the future is looking much better for Insite Vision.
Positive Phase 3 Results for BromSite™ announced
http://phx.corporate-ir.net/phoenix.zhtml?c=86061&p=irol-newsArticle&ID=1797497&highlight=
Will it rain today?
I like this one too. thanks poem. INSV
T
vizioman. Marked you. I have INSV as a sleeper that will awaken.
Heard Insite management had a meeting with Roth Capital last week, anyone heard more about that?
Interview (part 1) with TIm Ruane CEO of Insight Vision INSV on www.blackandwhiteprogram.com
http://blackandwhiteprogram.com/interview/interview-with-tim-ruane-ceo-of-insite-vision
I've been looking into this one for a while. Nice to see strong IR content on their website, including a new CEO blog. Anyone have any... InSite? (Sorry, couldn't help it.)
http://www.thechairmansblog.com/tim-ruane/
Insite Vision receives broad patent approval in Japan (INSV) 0.45 : Co announced that the Japanese Patent Office has issued a Notice to Patent with claims covering the formulation of azithromycin alone or combined with an anti-inflammatory agent, including dexamethasone, in an aqueous topical opththalmic suspension. The patent will expire on March 31, 2019. Japan is the third largest ophthalmic market in the world after the United States and the European Union.
think its gonna turn around here now.looks like they won patent infringement.and new chairman.chart kinda shows a pinch(2yr)
whats your thoughts rain
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
346
|
Created
|
06/03/09
|
Type
|
Free
|
Moderators |
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. Our mission is to develop and facilitate market entry for novel products worldwide that preserve and improve vision.
Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, is approved by the United States Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada for the treatment of bacterial conjunctivitis. AzaSite is formulated with our proprietary DuraSite® technology, which extends the residence time of the antibiotic azithromycin on the eye for several hours, thereby reducing the need for the frequent dosing regimen related to conventional anti-infective eye drops. AzaSite was launched in the U.S. in August 2007 by Inspire Pharmaceuticals, InSite’s commercial partner for the U.S. and Canada and will be marketed by international partners in Japan, Europe, South Korea, select countries in South America, Turkey and China upon approval in those countries. InSite will also pursue partnerships with companies who share our commitment to bringing innovative ophthalmic products such as AzaSite to patients worldwide.
AzaSite Plus (ISV-502), another product candidate in the AzaSite family, is currently in late-stage development for the treatment of eyelid infection and inflammation, specifically for the indication of blepharitis.
Our strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for our DuraSite-enabled early-stage product candidates, and applying our expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.
http://www.insitevision.com/partners
Commercial partnerships: InSite Vision receives royalty payments from our two commercial products, AzaSite® (azithromycin ophthalmic solution) 1% and Besivance™ (besifloxacin ophthalmic suspension) 0.6%. AzaSite is approved in the United States and Canada and marketed by InSite Vision’s partner, Inspire Pharmaceuticals. InSite Vision has also formed multiple strategic licensing and distribution agreements with partners to market AzaSite in select countries in Europe, Asia and South America upon regulatory approval in those regions. Besivance was approved by the U.S. Food and Drug Administration in 2009 and is being commercialized by Bausch & Lomb and Pfizer Inc. We work closely with our partners to support and extend product sales.
http://www.insitevision.com/product_pipeline
Phase Chart
Authorized Shares (AS) = 240 million
Outstanding Shares (OS) = 94.74 million
Restricted Shares = 21.73 million
Float = 73.01 million
http://finance.yahoo.com/q/ks?s=INSV.OB
INSV News
http://finance.yahoo.com/q/h?s=INSV.OB
INSV SEC Filings
http://finance.yahoo.com/q/sec?s=INSV.OB
INSV Management
· Louis Drapeau
Chief Executive Officer, Vice President and Chief Financial Officer
· Lyle M. Bowman, Ph.D.
Vice President, Development
· David Heniges
Vice President and General Manager, Commercial Opportunities
· Kamran Hosseini, M.D., Ph.D.
Vice President, Clinical Affairs and Chief Medical Officer
· Surendra Patel
Vice President, Operations and Quality
INSV Contact Information
http://finance.yahoo.com/q/pr?s=INSV.OB
Insite Vision Inc.
965 Atlantic Avenue
Alameda, CA 94501
United States - Map
Phone: 510-865-8800
Fax: 510-865-5700
Web Site: http://www.insitevision.com
Daily View
Weekly View
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |